Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Sold by Rhenman & Partners Asset Management AB

Rhenman & Partners Asset Management AB decreased its position in Nurix Therapeutics, Inc. (NASDAQ:NRIX) by 3.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 290,000 shares of the company’s stock after selling 10,000 shares during the quarter. Rhenman & Partners Asset Management AB owned 0.38% of Nurix Therapeutics worth $5,464,000 as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in NRIX. FMR LLC raised its holdings in shares of Nurix Therapeutics by 675.9% in the 3rd quarter. FMR LLC now owns 586,902 shares of the company’s stock valued at $13,188,000 after buying an additional 511,256 shares during the period. Lord Abbett & CO. LLC purchased a new stake in Nurix Therapeutics during the third quarter worth about $7,879,000. Vanguard Group Inc. lifted its position in shares of Nurix Therapeutics by 8.3% during the fourth quarter. Vanguard Group Inc. now owns 4,345,266 shares of the company’s stock worth $81,865,000 after purchasing an additional 333,452 shares in the last quarter. Norges Bank purchased a new position in shares of Nurix Therapeutics in the fourth quarter valued at approximately $6,006,000. Finally, Wellington Management Group LLP grew its holdings in shares of Nurix Therapeutics by 8.8% in the third quarter. Wellington Management Group LLP now owns 3,482,105 shares of the company’s stock valued at $78,243,000 after purchasing an additional 280,240 shares in the last quarter.

Nurix Therapeutics Price Performance

Shares of NRIX opened at $9.69 on Friday. The firm has a fifty day moving average price of $15.45 and a 200 day moving average price of $19.93. The stock has a market cap of $738.73 million, a PE ratio of -3.35 and a beta of 2.23. Nurix Therapeutics, Inc. has a 1-year low of $9.45 and a 1-year high of $29.56.

Nurix Therapeutics (NASDAQ:NRIX) last announced its earnings results on Tuesday, January 28th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.08). Nurix Therapeutics had a negative net margin of 354.85% and a negative return on equity of 53.65%. As a group, equities analysts expect that Nurix Therapeutics, Inc. will post -2.99 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have issued reports on NRIX. Stifel Nicolaus increased their target price on shares of Nurix Therapeutics from $34.00 to $36.00 and gave the stock a “buy” rating in a report on Wednesday, January 29th. Stephens reiterated an “overweight” rating and issued a $31.00 price objective on shares of Nurix Therapeutics in a research note on Tuesday, January 21st. Leerink Partnrs raised Nurix Therapeutics to a “hold” rating in a research note on Monday, March 17th. BMO Capital Markets started coverage on Nurix Therapeutics in a report on Friday, December 6th. They set an “outperform” rating and a $35.00 price target on the stock. Finally, JPMorgan Chase & Co. decreased their price objective on Nurix Therapeutics from $31.00 to $30.00 and set an “overweight” rating for the company in a research note on Wednesday, January 29th. Three investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $30.88.

Insider Transactions at Nurix Therapeutics

In other Nurix Therapeutics news, insider Gwenn Hansen sold 3,690 shares of Nurix Therapeutics stock in a transaction on Thursday, January 30th. The shares were sold at an average price of $19.85, for a total value of $73,246.50. Following the transaction, the insider now directly owns 55,937 shares in the company, valued at approximately $1,110,349.45. The trade was a 6.19 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Houte Hans Van sold 5,825 shares of the stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $14.49, for a total transaction of $84,404.25. Following the sale, the chief financial officer now owns 33,724 shares of the company’s stock, valued at $488,660.76. This trade represents a 14.73 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 12,326 shares of company stock worth $213,449. Insiders own 7.20% of the company’s stock.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.